Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ISEE

IVERIC bio (ISEE) Stock Price, News & Analysis

IVERIC bio logo

About IVERIC bio Stock (NASDAQ:ISEE)

Key Stats

Today's Range
$39.95
$39.95
50-Day Range
$36.90
$39.95
52-Week Range
$9.39
$39.99
Volume
N/A
Average Volume
3.62 million shs
Market Capitalization
$5.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.

Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Stock News Headlines

Astellas Pharma Inc (ALPMY)
Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
Apellis adds safety warning to eye therapy
Astellas Completes Acquisition of Iveric Bio
B.Riley Financial Sticks to Its Hold Rating for IVERIC bio (ISEE)
See More Headlines

ISEE Stock Analysis - Frequently Asked Questions

IVERIC bio, Inc. (NASDAQ:ISEE) posted its earnings results on Wednesday, March, 1st. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.10.

Based on aggregate information from My MarketBeat watchlists, some other companies that IVERIC bio investors own include Alibaba Group (BABA), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
3/01/2023
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ISEE
Fax
N/A
Employees
163
Year Founded
N/A

Profitability

Net Income
$-185,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.43 per share

Miscellaneous

Free Float
134,063,000
Market Cap
$5.50 billion
Optionable
Optionable
Beta
1.06
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:ISEE) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners